Status:
COMPLETED
The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia
Lead Sponsor:
Sutep Jaruratanasirikul
Collaborating Sponsors:
Prince of Songkla University
Conditions:
Ventilator-Associated Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is prospective, randomized and crossover design to assess the pharmacokinetic and pharmacodynamics of three regimen. * 0.5-hr infusion of imipenem 0.5 g every 6 hrs * 2-hr infusion of imipenem 0...
Detailed Description
Introduction: Ventilator-associated pneumonia (VAP) is a common cause of nosocomial infection with a high mortality rate. In the current era of increasing highly resistant pathogens in nosocomial infe...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years
- Patients are intubated and receiving mechanical ventilation.
- Patients have clinical suspicion of VAP with Gram negative bacilli infections, defined by a new and persistent infiltrate on chest radiography associated with at least one of the following: purulent tracheal secretions, temperature of 38.3°C or higher or a leucocyte count higher than 10000 cells/mm3.
- Expected life expectancy ≥ 3 days
Exclusion
- Patients have documented hypersensitivity to imipenem or other carbapenems.
- Patients have an estimated creatinine clearance \< 60 ml/min
- Patients are in circulatory shock (defined as a systolic blood pressure of \< 90 mmHg).
- Patients are pregnant.
- Pretient receive imipenem for 2 weeks before randomization.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT01489124
Start Date
January 1 2008
End Date
January 1 2009
Last Update
December 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand, 90110